Spots Global Cancer Trial Database for Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Official Title: A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University
Study ID: NCT00854620
Interventions
Study Description
Brief Summary: Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
Detailed Description: Sorafenib to be administered as 28-day cycles. Sorafenib dose escalation by cycle is: * Cycle 1: 400 mg BID * Cycle 2: 600 mg BID * Cycle 3+: 800 mg BID Within subject dose escalation and maximum dose is dependent on observed tolerability. Dose escalation only occurs after acceptable tolerability is demonstrated by subject.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Stanford University School of Medicine, Stanford, California, United States
Contact Details
Name: Dr. Sandy Srinivas
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
